Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure (ARF), Right Heart Failure, Unspecified
Conditions
Brief summary
This study aims to find out whether it is practical to introduce a consistent monitoring approach to the right side of the heart in patients supported with VV-ECMO. VV-ECMO is a life support machine that takes over the work of the lungs to give them time to recover. It is used when lung injury is life-threatening. Whilst receiving VV-ECMO support, in addition to the current standard of care, the following will be performed twice weekly: * Heart scan (echocardiogram) * Blood tests (hs-troponin and NT-proBNP) The patient's involvement in the study lasts for as long as they are on the life support machine, plus one final heart scan 48 hours after it is removed.
Interventions
DIAGNOSTIC_TESTTransthoracic echocardiogram
Transthoracic echocardiogram with a dedicated RV protocol
DIAGNOSTIC_TESTHigh sensitivity troponin
Twice weekly measurements
DIAGNOSTIC_TESTN-terminal pro-B-type natriuretic peptide
Twice weekly measurement.
Sponsors
Papworth Hospital NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (≥18 years old) * Less than 72 hours after being established on VV-ECMO due to SARF (either retrieved to RPH from another hospital or already an inpatient at RPH)
Exclusion criteria
* Patients \<18 years old * Patients that had been previously included in this study * Patients requiring VV-ECMO support post pulmonary thrombo-endarterectomy, as a bridge to lung transplantation or post lung-transplantation * Any other reason for VV-ECMO support that is not SARF * Patients and/or Personal Consultee not fluent in English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of RVI monitoring protocol | 2 months | Evaluate the feasibility of implementing a multimodal protocol for monitoring RVI in patients supported with VV-ECMO for severe acute respiratory failure at Royal Papworth Hospital Critical Care Area. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Echocardiography and biomarkers data | 2 months | Describe how specific RV echocardiographic parameters and biomarkers evolve over the course of VV-ECMO support. |
| Description of groups of patients | 12 months | Describe the following groups of patients: 1. With and without RVI 2. With and without early-RVI 3. With and without late-RVI 4. With mild, moderate and severe RVI 5. With RVI that meets and does not meet flow demand |
| Changes in patient's management | 2 months | Describe any changes in patient's management that were triggered by the results of the twice-weekly RVI monitoring protocol. |
Countries
United Kingdom
Contacts
CONTACTAna Francisca Caetano
Outcome results
None listed